Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and regorafenib in advanced hepatocellular carcinoma
NCT04806243Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- May 2021
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Nanfang Hospital, Southern Medical University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04806243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806243.